The purpose of this research study is to compare the effects of the study drug, PF 04965842, with a placebo to find out which is better for treating atopic dermatitis.
This study is to treat patients with Epidermolysis Bullosa Simplex (EBS) for whom topical treatments have not been developed. This study will evaluate the safety and efficacy of systemic treatment with Diacerein 1% Cream.
Participation in the study will take about 8 visits over a period of about 22 weeks, with a 6 week screening period, 8 weeks of treatment and 8 weeks of no-treatment follow up).
This study is to treat patients with moderate to severe atopic dermatitis for whom topical treatments have not been effective. This study will evaluate the safety and efficacy of systemic treatment with baricitinib.
Participation in the study will take about 16 visits over a period of about 26 months.
This is a clinical research trial that will evaluate whether an investigational drug called ixekizumab (given by injection) is safe and effective in children and young adults, ages 6 to 17, with moderate to severe plaque psoriasis. For more information, please call Abby Powell at (843) 792-6690.